Stock Research: J. B. Chemicals & Pharmaceuticals

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

J. B. Chemicals & Pharmaceuticals

BSE:506943 INE572A01028
79
  • Value
    75
  • Growth
    49
  • Safety
    Safety
    37
  • Combined
    50
  • Sentiment
    98
  • 360° View
    360° View
    79
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

J.B. Chemicals & Pharmaceuticals Limited is an India-based pharmaceutical company. It specializes in gastroenterology, hypertension, dermatology, nephrology, respiratory, virology, diabetes, and nicotine replacement therapy (NRT), manufacturing pharmaceutical formulations, herbal remedies, and APIs. Brands include Nicardia, Cilacar, Rantac, Metrogyl, and Cilacar-T. The company has a direct presence in Russia and South Africa, with distributor relationships in the United States, Asia, Africa, and Latin America. In the last fiscal year, the company had a market cap of $3005 millions, profits of $292 millions, revenue of $459 millions, and 5517 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 79 (better than 79% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock J. B. Chemicals & Pharmaceuticals are very positive. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for J. B. Chemicals & Pharmaceuticals. The consolidated Sentiment Rank has a good rank of 98, which means that professional investors are more optimistic about the stock than for 98% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 75 or better than 75% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 37, meaning that the share price of J. B. Chemicals & Pharmaceuticals is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 49. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 30-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
37 25 23 43
Growth
49 81 85 33
Safety
Safety
75 27 17 100
Sentiment
98 71 76 84
360° View
360° View
79 47 44 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
91 87 70 97
Opinions Change
41 14 40 50
Pro Holdings
n/a 68 27 63
Market Pulse
97 86 93 25
Sentiment
98 71 76 84
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
37 25 23 43
Growth
49 81 85 33
Safety Safety
75 27 17 100
Combined
50 27 23 79
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
42 33 30 49
Price vs. Earnings (P/E)
36 31 27 41
Price vs. Book (P/B)
28 24 28 50
Dividend Yield
53 28 45 39
Value
37 25 23 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
65 72 70 70
Profit Growth
54 67 78 10
Capital Growth
52 84 19 1
Stock Returns
45 53 89 91
Growth
49 81 85 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
89 44 36 84
Refinancing
30 22 28 64
Liquidity
79 44 40 90
Safety Safety
75 27 17 100

Similar Stocks

Discover high‑ranked alternatives to J. B. Chemicals & Pharmaceuticals and broaden your portfolio horizons.

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Dr. Reddy's

BSE:500124
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

L&T Finance Holdings

BSE:533519
Country: India
Industry: Other Financial Services
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.